immm
Lv5
850 积分
2022-11-07 加入
-
The antibody–drug conjugate landscape
13天前
已完结
-
Corporate Medicine 2.0 — Special Purpose Acquisition Companies in the United States
15天前
已完结
-
Novel drug targets in 2023
22天前
已关闭
-
The landscape of small-molecule prodrugs
22天前
已完结
-
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
24天前
已完结
-
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1个月前
已完结
-
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
1个月前
已完结
-
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
1个月前
已完结
-
Mechanisms of Dupilumab
2个月前
已完结